ReportsnReports publishes the report titled Cell Therapy Bioprocessing that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes
As a spate of researchers work diligently on next-gen CAR-T cell therapies, the big players in the current generation of those drugs are still angling for more market share. Getting to patients…
Bluebird relied largely on European patients enrolled in its beta-thalassemia clinical trials, though it’s withdrawn Zynteglo from Europe.
Kicking off this weekend’s #ASH21, Gilead’s Kite and Bristol Myers Squibb have released competing data for their current-gen CAR-T drugs in second-line B cell lymphoma patients. It’s a heated contest…
In a heated race with some of pharma’s biggest players, Roche’s Genentech is looking to drive a lead bispecific antibody program through the clinic against stubborn blood cancers. As the field watches…
Back in August, Servier revealed that a Phase III study for Tibsovo saw results so efficacious that investigators recommended stopping the trial early. Now at ASH, observers are getting a view at what…
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add…
Remember when medical meetings were live and in person? Stepping off the plane from Austin into this year’s American Society of Hematology annual meeting in Atlanta, I can’t help but feel some of the…
While a hematopoietic stem cell transplant is the best option for some patients with blood cancer, the procedure can lead to dangerous complications, such as graft-versus-host disease. Three…
A Researcher or Senior Researcher position is available in the laboratory of Dr. Myriam Labelle in the Department of Developmental Neurobiology at St. Jude Children’s Research Hospital. The Labelle…
